

ASX/Media Announcement

Perth: 20 April 2017

ENTITLEMENT OFFER - ALLOTMENT OF NEW SHARES

Lepidico Ltd (ASX:LPD) ("Lepidico" or "Company") announced on 18 April 2017 that valid acceptances had been received in respect of 238,659,066 shares ("New Shares") under the Company's Entitlement Offer.

The Company confirms that it has today allotted and issued the New Shares, and an ASX Appendix 3B in respect of the New Shares accompanies this announcement.

The New Shares are not currently subject to the unsolicited takeover offer made by Lithium Australia NL (ASX:LIT) ("Lithium Australia"), which, despite having received minimal acceptances to date, was recently extended by Lithium Australia until 5 May 2017.

The Company has been advised by ASX that the New Shares will initially trade under a separate code (ASX:LPDNC) until such time as the Lithium Australia takeover offer closes, or is varied to include the New Shares.

Your Directors reiterate their advice that Shareholders should in any case **REJECT** the ill-conceived and inadequate Lithium Australia scrip takeover offer, which the Independent Expert BDO has concluded is **neither fair nor reasonable**.

Further Information

For further information, please contact

Joe Walsh Managing Director Lepidico Ltd

Tel: +61 (0)8 9363 7800

Tom Dukovcic Exploration Director Lepidico Ltd

MEDIA ENQUIRIES John Gardner Citadel-MAGNUS

Tel: +61 (0)413 355 997

Website: <u>www.lepidico.com</u>

About Lepidico Ltd

Email: info@lepidico.com

Lepidico Ltd is an ASX-listed Company focused on exploration, development and production of lithium. Lepidico owns the technology to a metallurgical process that has successfully produced lithium carbonate from non-conventional sources, specifically lithium-rich mica minerals including lepidolite and zinnwaldite. The L-Max® Process has the potential to disrupt the lithium market by providing additional lithium supply from alternative sources. The Company is currently conducting a Feasibility Study for a Phase 1 L-Max® plant, targeting production for 2019. Four potential sources of feed to the planned Phase 1 Plant are being evaluated, one of which is the Separation Rapids deposit in Ontario, Canada in partnership with its owner Avalon Advanced Materials Inc.

Lepidico's current exploration assets include options over the Lemare and the Royal projects, both in Quebec, Canada; an ore access agreement with Grupo Mota over the Alvarrões Lepidolite Mine in



T: +61 8 9363 7800 E: info@lepidico.com Portugal; a farm-in agreement with Pioneer Resources (ASX:PIO) over the PEG 9 lepidolite prospect in Western Australia; ownership of the Euriowie amblygonite project near Broken Hill in New South Wales; and an agreement with ASX-listed Crusader Resources (ASX:CAS) on potential deployment of L-Max® in Brazil.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13$

ABN		
99 00	8 894 442	
We (th	ne entity) give ASX the following	information.
	1 - All issues st complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	238,659,066
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares

Name of entity

LEPIDICO LTD

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.013 per Share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Issue of Non-renounceable Entitlements Issue Shares (Entitlement Offer). As previously disclosed, the purpose of the Entitlement Offer was to raise funds to provide funding for the Definitive Feasibility Study for the Phase 1 L-Maz® Plant including associated exploration activities and working capital.
		**
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	25 November 2016
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued	Nil
ou	with security holder approval under rule 7.1A	1411

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	238,659,066	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 509,100,262 7.1A: 339,400,175 See Annexure 1 attache	ed.
7	⁺ Issue dates	20 April 2017	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	20 April 2017	
			1.01
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number 1,989,196,657* *Of which 238,659,066 are initially to be traded separately under the code LPDNC	+Class Ordinary Shares*

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

9 Number and +class of all ⁺securities not quoted on ASX (including the $^+$ securities in section 2 if applicable)

Number	⁺ Class
	Options
27,750,000	Unlisted Options with exercise price of 3.0 cents and expiring 30 September 2017
40,000,000	Unlisted Options with exercise price of 1.815 cents and expiring 3 August 2018
9,000,000	Unlisted Options with exercise price of 1.0 cents and expiring 31 December 2018
50,000,000	Unlisted Director Incentive Options with exercise price of 2.5 cents and expiring 31 December 2019
25,000,000	Unlisted Incentive Options with exercise price of 2.5 cents and expiring 31 December 2019 (of which 12,500,000 are subject to vesting period, to be automatically waived in the event of a Change of Control event)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Pro rata issue

11 Is security holder approval required?

No

12 Is the issue renounceable or nonrenounceable?

Non-renounceable

13 Ratio in which the *securities will be offered

1 New Share for every 4 shares held

⁺Class of ⁺securities to which the Fully Paid Ordinary Shares 14 offer relates

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

15	⁺ Record date to determine entitlements	21 March 2017
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	Fractional entitlements rounded up to the nearest whole number
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	All countries except Australia and New Zealand.
19	Closing date for receipt of acceptances or renunciations	Offer Closed on 12 April 2017
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Nil
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	22 March 2017

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Appendix 3B New issue announcement

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A	
28	Date rights trading will begin (if applicable)	N/A	
29	Date rights trading will end (if applicable)	N/A	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	NA	
33	⁺ Issue date	20 April 2017	
Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities Type of *securities (tick one)			
(a)	*Securities described in Part 1		
(b)	All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entities that have ticked box 34(a)			
Additional securities forming a new class of securities (N/A)			
Tick to indicate you are providing the information or documents			

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

35	If the $^+$ securities are $^+$ equity securities, the names of the 20 largest holders of the additional $^+$ securities, and the number and percentage of additional $^+$ securities held by those holders
36	If the $^+$ securities are $^+$ equity securities, a distribution schedule of the additional $^+$ securities setting out the number of holders in the categories 1 - $1,000$ $1,001$ - $5,000$ $5,001$ - $10,000$ $10,001$ - $100,000$ $100,001$ and over
37	A copy of any trust deed for the additional *securities

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Entities that have ticked box 34(b) 38 Number of *securities for which ⁺quotation is sought ⁺Class of ⁺securities for which 39 quotation is sought 40 Do the *securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) interest or payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest or payment 41 Reason for request for quotation Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other +security) Number +Class 42 +class Number and of all ASX ⁺securities quoted on (including the +securities in clause

38)

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Company secretary)	Date: 20 April 2017
Print name:	Alex Neuling	
	== == == ==	

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue			584,350,921
Add the following:			
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	Option Exercise Rights Issue Option Exercise Listed Option Exercises Listed Option Exercises Rights Issue Acquisition Consideration Critical Elements farmin for Lemare Property	21/04/2016 27/04/2016 6/05/2016 13/05/2016 2/06/2016 3/06/2016 8/06/2016 29/06/2016 6/07/2016 25/11/2016 21/2/2016 20/04/2016	16,666,668 4,000,000 11,806 6,000,000 1,000,000 108,894 12,507 2,500 367,290,477 2,500,000 38,234 40,645 238,659,066 636,290,152 750,000,000 18,514,939 768,514,939
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period			-
Note: Include only ordinary securities here other classes of equity securities cannot be added Include here (if applicable) the			

⁺ See chapter 19 for defined terms.

Appendix 3B Page 10 04/03/2013

securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on	
different dates as separate line items	
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-
"A"	3,394,001,748

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	509,100,262	
Step 3: Calculate "C", the amount that has already been used	of placement capacity under rule 7.1	
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	-	
Under an exception in rule 7.2		
• Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	-	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	509,100,262	
Note: number must be same as shown in Step 2		
Subtract "C"	-	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	509,100,262	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	3,394,001,748	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"	,	
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	339,400,175	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	-	

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	339,400,175
Note: number must be same as shown in Step 2	
Subtract "E"	-
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	339,400,175
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 04/03/2013

⁺ See chapter 19 for defined terms.